Castle Biosciences, Inc. Revenue 2018–2025
Castle Biosciences, Inc. annual/quarterly revenue history and growth rate from 2018 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Castle Biosciences, Inc. revenue for the quarter ending March 31, 2026 was 83.7 M, a 4.90% decrease year-over-year.
- Castle Biosciences, Inc. revenue for the twelve months ending March 31, 2026 was 340.9 M, a 10.95% increase year-over-year.
- Castle Biosciences, Inc. annual revenue for 2025 was 344.2 M, a 3.66% increase from 2024.
- Castle Biosciences, Inc. annual revenue for 2024 was 332.1 M, a 51.09% increase from 2023.
- Castle Biosciences, Inc. annual revenue for 2023 was 219.8 M, a 60.38% increase from 2022.
- Castle Biosciences, Inc. annual revenue for 2022 was 137.0 M.
Castle Biosciences, Inc. (CSTL) — Frequently Asked Questions
Castle Biosciences, Inc. (CSTL) is a publicly traded US company. It has a market capitalization of $611M. In fiscal 2025 it reported revenue of $344M and net income of -$24M. Explore CSTL's stock price, financial statements, earnings history, margins and key ratios below.
What is Castle Biosciences, Inc.'s market cap?
Castle Biosciences, Inc. (CSTL) has a market capitalization of $611M.
What is the CSTL stock price?
CSTL trades at $21.08.
How much revenue does Castle Biosciences, Inc. make?
Castle Biosciences, Inc. reported revenue of $344M in fiscal 2025.
Is CSTL profitable?
In fiscal 2025, Castle Biosciences, Inc. reported net income of -$24M.